Clinical trials: Cannabidiol
ASD, Autism Spectrum Disorder
Cannabidiol for ASD Open Trial
This is a 6-week open trial to identify the optimal dosing of cannabidiol (CBD) in youth with autism spectrum disorder (ASD) and to identify primary and secondary outcomes for future controlled studies.
- Trial name
- NCT03900923
- Testing
- 98% pure CBD
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- NYU Langone Health
Metabolism, Liver Function
Interaction Between Cannabidiol, Meal Ingestion, and Liver Function
According to a recent consumer poll, over 20 million Americans regularly use cannabidiol (CBD). Moreover, 64 million Americans (over 25% of the population) report trying CBD at least once within the previous 2 years.
- Conditions
- Metabolism, Liver Function, Pharmacokinetics
- Trial name
- NCT04971837
- Testing
- Cannabidiol (CBD) powder formulation, Cannabidiol (CBD) Oil based tincture formulation, Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Epilepsy, Dravet Syndrome
An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- GWPCARE5 (NCT02224573)
- Testing
- GWP42003-P
- Volunteers
- 681 people
- Sponsor
- GW Research Ltd
Chronic Pain
Mechanisms of CBD for Chronic Pain
This is a study designed to examine the neurochemical mechanisms associated with Cannabidiol (CBD) versus placebo for chronic non-cancer pain.
- Trial name
- NCT04044729
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Drug Addiction
Cannabidiol and Emotional Stimuli
The purpose of this research is to examine the effect of cannabidiol (CBD), a cannabinoid compound found in marijuana, on responses to emotional stimuli.
- Trial name
- CAS (NCT02902081)
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Opioid Withdrawal, Opioid Craving
Oral Cannabidiol for Opioid Withdrawal
This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal.
- Conditions
- Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
- Trial name
- NCT04238754
- Testing
- Epidiolex
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Opiate Addiction
Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans
Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal…
- Trial name
- NCT02539823
- Testing
- CBD 400 mg, CBD 800 mg
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Hurd,Yasmin, Ph.D.
Perceptions
Consumer Perceptions of Cannabidiol (CBD) Health Claims
Over 46 million US adults report use of cannabidiol (CBD), primarily to treat medical ailments. The growing CBD market spans the range of products that the US Food and Drug Administration (FDA) regulates including drugs, dietary…
- Trial name
- CBD (NCT06069713)
- Testing
- CBD advertisements
- Where
- United States
- Volunteers
- 3,504 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Epilepsy
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record.
- Trial name
- NCT02565108
- Testing
- GWP42003-P 20 mg/kg/Day Dose, Clobazam
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Jazz Pharmaceuticals
CBD, Hand Osteoarthritis
Is Topical CBD Effective in Treating Thumb Joint Arthritis
Rationale: CBD is commonly being used as an over-the-counter treatment for arthritis-related pain, however no clinical trial has been performed to establish efficacy.
- Trial name
- NCT04611347
- Testing
- CBD, Shea Butter
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Sturge-Weber Syndrome
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
The purpose of this study is to determine the tolerability and optimal dose of cannabidiol (CBD) as an simultaneous treatment in children and young adults with Sturge-Weber syndrome (SWS) and drug resistant epilepsy.
- Trial name
- NCT02332655
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Anne Comi, MD
PTSD
Cannabidiol and Prolonged Exposure
The trial will include a randomized control trial to evaluate the efficacy of using Cannabidiol (CBD), a non-intoxicating cannabinoid, as an adjunctive to Prolonged Exposure therapy (PE).
- Trial name
- CBD-PE (NCT03518801)
- Testing
- Prolonged Exposure, Cannabidiol
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- VA Office of Research and Development
Epilepsy, Dravet Syndrome
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
- Trial name
- NCT02091375
- Testing
- GWP42003-P 20 mg/kg/day Dose
- Where
- 22 sites in United States, France and 2 more
- Volunteers
- 120 people
- Sponsor
- Jazz Pharmaceuticals
Alexithymia, HIV
Role of CBD in Improving Alexithymia
Given the treatments that are available today for HIV disease, people living with HIV (PLWH) can generally expect good medical outcomes.
- Trial name
- ACBD (NCT05832281)
- Testing
- Purysis CBD
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Diego
Infantile Spasms
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. The open-label extension phase only will be described in this record.
- Trial name
- NCT02954887
- Testing
- GWP42003-P
- Where
- 7 sites in United States, Poland
- Volunteers
- 9 people
- Sponsor
- Jazz Pharmaceuticals
Opioid-use Disorder
Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
This research aims to determine the effects and safety of cannabidiol (CBD) (ATL5 softgel capsules) as an adjunctive therapy for patients who have Opioid Use Disorder and are taking buprenorphine + naloxone or methadone.
- Trial name
- NCT03787628
- Testing
- Cannabidiol (CBD) 600 mg
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Los Angeles
Opiate Addiction
Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans
Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal…
- Trial name
- NCT01605539
- Testing
- Cannabidiol 400, Cannabidiol 800, Control
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hurd,Yasmin, Ph.D.
Back Pain, Low
Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain
In this research, the study team will use brain imaging to evaluate the presence of neuroinflammation in the brains and spinal cords of patients with low back pain, and whether CBD effects levels of neuroinflammation.
- Trial name
- CBD (NCT03891264)
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Multiple Sclerosis
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An open-label extension study in which patients with multiple sclerosis received GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] for four weeks in an open-label manner.
- Trial name
- NCT01610713
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 154 people
- Sponsor
- Jazz Pharmaceuticals
Fatty Liver
Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease
The purpose of this study is to evaluate the effect of GWP42003 on liver triglyceride (liver fat) in participants with fatty liver disease (FLD).
- Trial name
- NCT01284634
- Testing
- GWP42003 200 mg/day Dose, GWP42003 400 mg/day Dose, GWP42003 800 mg/day Dose
- Where
- 3 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- GW Research Ltd